Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug combo reawaken the immune system against resistant cancers?

NCT ID NCT07718243

Not yet recruiting Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of nivolumab, then tests that dose in patients with these cancers. Early research suggests bexmarilimab may change immune cells inside the tumor to create a stronger attack signal, potentially helping nivolumab work again.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of bexmarilimab and nivolumab
What this could lead to
If it works, this could offer a new treatment option for people whose cancers no longer respond to standard immunotherapy.
What could go wrong
This is an early-phase trial with a small number of participants, so the combination may not prove effective or safe enough for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN CANCER) NON-SMALL CELL LUNG CANCER SOLID TUMOR IN ADVANCED STAGE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Royal Marsden NHS Foundation Trust - Drug Development Unit

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.